Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab for prevention of periprocedural myocardial injury in elective PCI
ChiCTR2200063191Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of alirocumab in coronary arteriosclerosis, Myocardial injury and myocardial infarction (MI) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: cardiac troponin elevation 12–24 hours after PCI. Started Sep 2022; status: recruiting.
02
Drugs
alirocumab
03
Conditions
coronary arteriosclerosisMyocardial injurymyocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2200063191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063191.